AC0010MA

DRUG2 trials

Sponsors

ACEA Therapeutics, Inc., Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Conditions

B-cell LymphomaNon Small Cell Lung Cancer

Phase 1

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

TerminatedNCT02448251

ACEA Therapeutics, Inc.Non Small Cell Lung Cancer

Start: 2015-05-31End: 2019-10-31Updated: 2019-10-29

A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL

Hangzhou ACEA Pharmaceutical Research Co., Ltd.B-cell Lymphoma

Start: 2017-03-17End: 2020-12-14Target: 184Updated: 2019-02-01

Related Papers

PF515 A PHASE I STUDY OF THE BTK INHIBITOR ABIVERTINIB (AC0010) IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL LYMPHOMA

HemaSphere2019-06-013 citations